Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer

Non-clear cell renal cell carcinoma: Management of papillary RCC

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

Bladder cancer updates from the first half of 2025

Supportive care intervention improves function and reduces fatigue in older lung cancer patients

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression

WCLC 2025: Latest in EGFR positive NSCLC